Sellas Life Sciences Group Inc to Host Key Opinion Leader Webinar Transcript
Good morning, and welcome to the SELLAS Life Sciences Group KOL event. (Operator Instructions) As a reminder, this webinar is being recorded, and a replay will be made available on the SELLAS website following the conclusion of the event.
Before we begin, I'd like to make reference to the forward-looking statements slide on the screen.
I'd now like to turn the call over to your host, Dr. Angelos Stergiou, Founder, President and Chief Executive Officer of SELLAS Life Sciences Group.
Thank you very much, Tara, and good morning, everyone, and thank you for joining us today for our KOL webinar to discuss SELLAS's Phase III clinical trial of galinpepimut-S, or GPS, in patients with acute myeloid leukemia in second remission, the REGAL study. We're privileged to be joined by renowned hematologist-oncologist, Dr. Omer Jamy, who is a REGAL study principal investigator at the University of Alabama at Birmingham, one of the highest enrolling REGAL sites. Dr.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |